Zydus Cadila Healthcare Limited - Product Pipeline Review - H2 2011
Global Markets Direct
November 28, 2011 88 Pages - SKU: GMD6692333
|
|
Zydus Cadila Healthcare Limited - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Zydus Cadila Healthcare Limited - Product Pipeline Review - H2 2011” provides data on the Zydus Cadila Healthcare Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Zydus Cadila Healthcare Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Zydus Cadila Healthcare Limited and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope - Zydus Cadila Healthcare Limited - Brief Zydus Cadila Healthcare Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Zydus Cadila Healthcare Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Zydus Cadila Healthcare Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Zydus Cadila Healthcare Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy - Evaluate Zydus Cadila Healthcare Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Zydus Cadila Healthcare Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Zydus Cadila Healthcare Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Zydus Cadila Healthcare Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Zydus Cadila Healthcare Limited and identify potential opportunities in those areas.
|
- Zydus Cadila Healthcare Limited Snapshot
- Zydus Cadila Healthcare Limited Overview
- Key Information
- Key Facts
- Zydus Cadila Healthcare Limited - Research and Development Overview
- Key Therapeutic Areas
- Zydus Cadila Healthcare Limited - Pipeline Review
- Pipeline Products by Stage of Development
- Zydus Cadila Healthcare Limited - Pipeline Products Glance
- Zydus Cadila Healthcare Limited - Late Stage Pipeline
- Phase III Products/Combination Treatment Modalities
- Zydus Cadila Healthcare Limited Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- Zydus Cadila Healthcare Limited-Early Stage Pipeline Products
- Pre-Clinical Products/Combination Treatment Modalities
- Discovery Products/Combination Treatment Modalities
- Zydus Cadila Healthcare Limited - Drug Profiles
- Blonanserin
- Product Description
- Mechanism of Action
- R&D Progress
- Drug For Atherosclerotic Plaque
- Product Description
- Mechanism of Action
- R&D Progress
- MAb 1
- Product Description
- Mechanism of Action
- R&D Progress
- MAb 2
- Product Description
- Mechanism of Action
- R&D Progress
- MAb 3
- Product Description
- Mechanism of Action
- R&D Progress
- MAb 4
- Product Description
- Mechanism of Action
- R&D Progress
- Oral GLP-1 Agonist
- Product Description
- Mechanism of Action
- R&D Progress
- Oral PTH Agonist
- Product Description
- Mechanism of Action
- R&D Progress
- PEG-EPO
- Product Description
- Mechanism of Action
- R&D Progress
- Prod 1
- Product Description
- Mechanism of Action
- R&D Progress
- Prod 2
- Product Description
- Mechanism of Action
- R&D Progress
- Prod 3
- Product Description
- Mechanism of Action
- R&D Progress
- Prod 4
- Product Description
- Mechanism of Action
- R&D Progress
- Prod 5
- Product Description
- Mechanism of Action
- R&D Progress
- Prod 6
- Product Description
- Mechanism of Action
- R&D Progress
- ZY01
- Product Description
- Mechanism of Action
- R&D Progress
- ZYD1
- Product Description
- Mechanism of Action
- R&D Progress
- ZYH1
- Product Description
- Mechanism of Action
- R&D Progress
- ZYH2
- Product Description
- Mechanism of Action
- R&D Progress
- ZYH3
- Product Description
- Mechanism of Action
- R&D Progress
- ZYH7
- Product Description
- Mechanism of Action
- R&D Progress
- ZYI1
- Product Description
- Mechanism of Action
- R&D Progress
- ZYOG1
- Product Description
- Mechanism of Action
- R&D Progress
- ZYT1
- Product Description
- Mechanism of Action
- R&D Progress
- Zydus Cadila Healthcare Limited - Pipeline Analysis
- Zydus Cadila Healthcare Limited - Pipeline Products by Therapeutic Class
- Zydus Cadila Healthcare Limited - Pipeline Products By Target
- Zydus Cadila Healthcare Limited - Pipeline Products by Route of Administration
- Zydus Cadila Healthcare Limited - Pipeline Products by Molecule Type
- Zydus Cadila Healthcare Limited - Recent Pipeline Updates
- Zydus Cadila Healthcare Limited - Company Statement
- Zydus Cadila Healthcare Limited - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Mar 31, 2009: Zydus Receives FDA Approval For Topiramate Tablets
- Aug 30, 2007: Zydus Cadila Files 5th IND To ZYH7 For The Treatment Of Dyslipidemia And Metabolic Disorders
- Aug 30, 2007: Zydus Cadila files IND application for NME - ZYH2
- Apr 28, 2010: Zydus Receives FDA Approval For Tamsulosin Capsules
- Jun 21, 2010: Zydus' ZYOG1 Enters Phase I Clinical Trial For Treatment Of Diabetes And Obesity
- Oct 20, 2008: Zydus receives Approval For Risperidone tablets
- May 17, 2010: Zydus Cadila To Launch H1N1 Vaccine In India
- Dec 16, 2005: Zydus Cadila Files Its Second IND Application For NME - ZYI1
- Oct 16, 2008: Zydus Files IND Application For ZYT1, A Novel Candidate To Treat Dyslipidemia
- Oct 14, 2010: Zydus Cadila launches Pramipexole Tablets in the US market
- Aug 12, 2010: Zydus Joins WHO To Develop MAb Cocktail For Rabies
- Mar 12, 2007: Zydus receives approval for Paroxetine Tablets
- Oct 07, 2010: Zydus Cadila Receives FDA Approval For Losartan Potassium And Hydrochlorothiazide Tablets
- Apr 07, 2011: Zydus’s IND Application Of ZYGK1 For Treating Diabetes Receives FDA Approval
- May 05, 2009: Zydus Receives FDA Approval For Mycophenolate Mofetil Tablets And Capsules
- Jun 04, 2009: Zydus Files IND Application With The DCGI For ‘ZYD1’ - A Novel Candidate To Treat Diabetes And Obesity
- Jan 04, 2010: Zydus Cadila To Start Clinical Trials Of H1N1 Vaccine
- Jun 03, 2010: Zydus Cadila Healthcare Launches Vaxiflu-S H1N1 Vaccine In India
- Jun 03, 2005: Zydus Cadila Commences Phase I Clinical Trials Of ZYH1
- Apr 02, 2009: Zydus Files IND Application With The USFDA For ZYT1, A Novel Candidate To Treat Dyslipidemia
- Financial Deals Landscape
- Zydus Cadila Healthcare Limited, Deals Summary
- Zydus Cadila Healthcare Limited, Pharmaceuticals & Healthcare, Deal Details
- Partnerships
- Karo Bio Extends Research Agreement With Zydus Cadila
- Bayer HealthCare Enters Into Joint Venture Agreement With Zydus Cadila Healthcare
- Zydus Cadila Expands Its Co-Marketing Agreement With Bayer Schering
- Zydus Cadila Signs An Agreement With Eli Lilly
- Nycomed Signs An Agreement With Zydus Cadila
- Karo Bio Enters Into An Agreement With Zydus Cadila
- Zydus Cadila Enters Into Co-Development With Prolong Pharmaceuticals
- Zydus Cadila Enters Into Joint Venture With TGL Enterprises
- Zydus Cadila Healthcare Forms Joint Venture With Bharat Serums and Vaccines
- Zydus Cadila Healthcare Enters Into An Agreement With Zambon Company
- Cadila Healthcare Forms Joint Venture With Mayne Pharma
- Zydus Cadila Enters Into Co-Marketing Agreement With Mallinckrodt
- Zydus Cadila Healthcare Enters Into An Agreement With Boehringer Ingelheim India
- Licensing Agreements
- Abbott Enters Into Licensing Agreement With Zydus Cadila
- Debt Offering
- Cadila Healthcare Announces Public Offering Of Bonds For $33.5 Million
- Acquisition
- Cadila Healthcare Acquires Remaining 30% Stake In Simayla Pharmaceuticals
- Cadila Healthcare Acquires 30% Stake In Zydus Pharmaceuticals USA
- Zydus Cadila Acquires Etna Biotech From Crucell
- Cadila Healthcare Acquires 70% Stake In Simayla Pharmaceuticals
- Cadila Healthcare Acquires Laboratorios Combix
- Zydus Healthcare Brasil Acquires Quimica e Farmaceutica Nikkho do Brasil
- Cadila Healthcare Acquires Nippon Universal Pharmaceutical
- Zydus Cadila Healthcare Acquires Liva Healthcare
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Zydus Cadila Healthcare Limited - Pipeline by Therapy Area and Indication, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, H2 2011
- Zydus Cadila Healthcare Limited - Phase III, H2 2011
- Zydus Cadila Healthcare Limited - Phase II, H2 2011
- Zydus Cadila Healthcare Limited - Phase I, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Therapeutic Class, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Target, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Route of Administration, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Molecule Type, H2 2011
- Zydus Cadila Healthcare Limited - Recent Pipeline Updates, H2 2011
- Zydus Cadila Healthcare Limited, Subsidiaries
- Zydus Cadila Healthcare Limited, Deals Summary
- Karo Bio Extends Research Agreement With Zydus Cadila
- Bayer HealthCare Enters Into Joint Venture Agreement With Zydus Cadila Healthcare
- Zydus Cadila Expands Its Co-Marketing Agreement With Bayer Schering
- Zydus Cadila Signs An Agreement With Eli Lilly
- Nycomed Signs An Agreement With Zydus Cadila
- Karo Bio Enters Into An Agreement With Zydus Cadila
- Zydus Cadila Enters Into Co-Development With Prolong Pharmaceuticals
- Zydus Cadila Enters Into Joint Venture With TGL Enterprises
- Zydus Cadila Healthcare Forms Joint Venture With Bharat Serums and Vaccines
- Zydus Cadila Healthcare Enters Into An Agreement With Zambon Company
- Cadila Healthcare Forms Joint Venture With Mayne Pharma
- Zydus Cadila Enters Into Co-Marketing Agreement With Mallinckrodt
- Zydus Cadila Healthcare Enters Into An Agreement With Boehringer Ingelheim India
- Abbott Enters Into Licensing Agreement With Zydus Cadila
- Cadila Healthcare Announces Public Offering Of Bonds For $33.5 Million
- Cadila Healthcare Acquires Remaining 30% Stake In Simayla Pharmaceuticals
- Cadila Healthcare Acquires 30% Stake In Zydus Pharmaceuticals USA
- Zydus Cadila Acquires Etna Biotech From Crucell
- Cadila Healthcare Acquires 70% Stake In Simayla Pharmaceuticals
- Cadila Healthcare Acquires Laboratorios Combix
- Zydus Healthcare Brasil Acquires Quimica e Farmaceutica Nikkho do Brasil
- Cadila Healthcare Acquires Nippon Universal Pharmaceutical
- Zydus Cadila Healthcare Acquires Liva Healthcare
- List of Figures
- Zydus Cadila Healthcare Limited - Pipeline by Therapy Area and Indication, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Therapeutic Class, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Target, H2 2011
- Zydus Cadila Healthcare Limited - Pipeline By Molecule Type, H2 2011
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
